Patent classifications
C07K16/04
Immunoglobulin polypeptide fractions from products of domestic animals
The present invention provides a means to prepare a product from domestic animal milk, blood or eggs which comprises an array of T-cell exposed motifs similar in identity, distribution and concentration to those found in human immunoglobulin variable regions and to prepare and apply the product as an immune modulating agent for administration either as a nutritional supplement or as a pharmaceutical product.
Immunoglobulin polypeptide fractions from products of domestic animals
The present invention provides a means to prepare a product from domestic animal milk, blood or eggs which comprises an array of T-cell exposed motifs similar in identity, distribution and concentration to those found in human immunoglobulin variable regions and to prepare and apply the product as an immune modulating agent for administration either as a nutritional supplement or as a pharmaceutical product.
METHODS FOR IDENTIFYING AND TREATING ADRENOMYELONEUROPATHY (AMN)
Provided herein is a method of detecting adrenomyeloneuropathy (AMN) in a human male subject, said method comprising determining the level of MFGE8, C1qa, Trem2, Gas6 or any combination thereof, in a biological sample obtained from the spine of the subject, wherein said level or levels are increased compared to a reference level or levels, thereby detecting AMN in the subject. Also provided is a method of treating AMN in a human male subject, said method comprising administering an anti-MFGE8 antibody to the subject.
ANTIBODY PURIFICATION
The present invention relates to methods for purifying heterologous antibodies from caprine milk, such as goat milk. The present invention includes protein A based affinity chromatography to obtain purified transgenically expressed antibodies, in particular concentrates free from endogenous caprine antibodies.
ANTIBODY PURIFICATION
The present invention relates to methods for purifying heterologous antibodies from caprine milk, such as goat milk. The present invention includes protein A based affinity chromatography to obtain purified transgenically expressed antibodies, in particular concentrates free from endogenous caprine antibodies.
AFUCOSYLATED MONOCLONAL ANTIBODY
Provided is an afucosylated monoclonal antibody. The monoclonal antibody is a human IgG antibody and has an afucosylated sugar chain structure at a heavy-chain sugar chain binding site. Also provided are application of the monoclonal antibody in the preparation of antineoplastic drugs, and a composition containing the monoclonal antibody. Compared with a fucosylated monoclonal antibody, the provided afucosylated monoclonal antibody has higher biological activity in vitro and in vivo and can be used for developing more effective therapeutic monoclonal antibody drugs.
ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE
The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.
ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE
The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies or compositions comprising the antibodies can be used to treat disease in which ADCC activity provides a benefit. In one embodiment, therefore, the antibodies or compositions comprising the antibodies can be used to treat cancer, lymphoproliferative disease or autoimmune disease.
STABLE POOLED BREASTMILK ANTIBODIES FOR ORAL DELIVERY
Methods are provided for extracting and purifying maternal antibodies from breastmilk, followed by further processing to facilitate oral ingestion. The methods may be used on breastmilk from any mammal, including humans, for consumption by mammals including humans. Antibodies are well-known immune mediators that are naturally found in abundant supply in breastmilk, and they are passed directly to the offspring via breastfeeding. The methods described herein extract antibodies from breastmilk in a manner that preserves the structure and antigen-specificity while enabling the formulation into products that are optimized for delivery to mammals, including humans. The method comprises (1) breastmilk collection, (2) extraction of antibodies, (3) characterization of antibody structure, degradation, and contamination, and (4) formulation into a dietary supplement (food product) for delivery to mammals, especially humans.
STABLE POOLED BREASTMILK ANTIBODIES FOR ORAL DELIVERY
Methods are provided for extracting and purifying maternal antibodies from breastmilk, followed by further processing to facilitate oral ingestion. The methods may be used on breastmilk from any mammal, including humans, for consumption by mammals including humans. Antibodies are well-known immune mediators that are naturally found in abundant supply in breastmilk, and they are passed directly to the offspring via breastfeeding. The methods described herein extract antibodies from breastmilk in a manner that preserves the structure and antigen-specificity while enabling the formulation into products that are optimized for delivery to mammals, including humans. The method comprises (1) breastmilk collection, (2) extraction of antibodies, (3) characterization of antibody structure, degradation, and contamination, and (4) formulation into a dietary supplement (food product) for delivery to mammals, especially humans.